I have 2 questions for Robert Myers and colleagues concerning their recent practice guideline on baseline staging tests in primary breast cancer.1 What do they call “biochemical evidence of metastases?” Which marker(s) and cut-off(s) do they suggest be used? Answers to these questions might make their guideline evidence-based, as far as laboratory medicine is concerned.
Reference
- 1.